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Abstract: A series of thiazolidin-4-one (2a–h; 3a–h), azetidin-2-one (4a–h) and 
1,3,4-oxadiazole (5a–h)  derivatives of  isoninicotinic acid hydrazide (INH) 
were synthesized in order to obtain new compounds with potential anti-inflam-
matory, analgesic, ulcerogenic and lipid peroxidation activities. The structures 
of the new compounds were supported by their IR, 1H-NMR and mass spectral 
data. All compounds were evaluated for their anti-inflammatory activity by the 
carrageenan-induced rat paw edema test method. Eleven of the new com-
pounds, out of 32, showed very good anti-inflammatory activity in the carra-
geenan-induced rat paw edema test, with significant analgesic activity in the 
tail immersion method together with negligible ulcerogenic action. The com-
pounds, which showed less ulcerogenic action, also showed reduced malondial-
dehyde content (MDA), which is one of the by-products of lipid peroxidation. 
The study showed that the compounds inhibited the induction of gastric mu-
cosal lesions and it can be suggested from the results that their protective ef-
fects may be related to inhibition of lipid peroxidation in the gastric mucosa. 
Keywords: anti-inflammatory activity; analgesic activity; ulcerogenic activity; 
lipid peroxidation. 
INTRODUCTION 
The currently available non-steroidal anti-inflammatory drugs (NSAIDs), 
such as ibuprofen, flurbiprofen, fenbufen and naproxen, exhibit gastric toxicity. 
Long-term use of these drugs has been associated with gastro-intestinal (GI) ul-
ceration, bleeding and nephrotoxicity.1 The pharmacological activity of NSAIDs 
is related to the suppression of prostaglandin biosynthesis from arachidonic acid 
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by inhibiting the enzyme cyclooxygenases (COXs).2,3 Recently, it was disco-
vered that COX exists in two isoforms, COX-1 and COX-2, which are regulated 
differently.4–6 COX-1 provides cytoprotection in the gastrointestinal (GI) tract, 
whereas inducible COX-2 mediates inflammation.7–9 Since most of the NSAIDs 
on the market show greater selectivity for COX-1 than COX-2,10 chronic use of 
NSAIDs may elicit appreciable GI irritation, bleeding and ulceration. 
The GI damage from NSAIDs is generally attributed to two factors, i.e., lo-
cal irritation by the carboxylic acid moiety common to most NSAIDs (topical ef-
fect); and decreased tissue prostaglandin production, which undermines the phy-
siological role of the cytoprotective prostaglandins in maintaining GI health and 
homeostasis.11 The incidence of clinically significant GI side effects due to 
NSAIDs is high (30 %) and causes some patients to abandon NSAID therapy.12 
Thus, the discovery of COX-2 provided the rationale for the development of drugs 
devoid of GI disorders while retaining clinical efficacy as anti-inflammatory 
agents. However, recent reports showed that selective COX-2 inhibitors (coxibs) 
could lead to adverse cardiovascular effects.13 Therefore, the development of no-
vel compounds having anti-inflammatory and analgesic activity with improved 
safety profiles is still a necessity. 
Synthetic approaches based on chemical modification of NSAIDs have been 
undertaken with the aim of improving their safety profiles. A literature survey 
revealed that derivatization of the carboxylate function of NSAIDs resulted in re-
tained anti-inflammatory activity with reduced ulcerogenic potential.14–17 It has 
also been reported in the literature that certain compounds bearing a thiazolidin- 
-4-one, azetidin-2-one or 1,3,4-oxadiazole nucleus possess significant anti-in-
flammatory activity.18–20 
In view of the important biological properties of the thiazolidin-4-one, aze-
tidin-2-one and 1,3,4-oxadiazole nuclei, it was planned to suitably incorporate 
the above-mentioned ring systems into the isoniazide moiety to explore the pos-
sibilities of some altered biological actions. Hence, the thiazolidin-4-one, azeti-
din-2-one and 1,3,4-oxadiazole derivatives reported herein were designed and 
synthesized. They were found to possess an interesting profile of anti-inflam-
matory and analgesic activity with significant reduction in their ulcerogenic risks 
to the stomach. 
EXPERIMENTAL 
Materials, methods and instrumentation 
All the solvents were of AR grade and were obtained from Merck, CDH and S.D. Fine 
chemicals. Melting points were determined in open capillary tubes and are uncorrected. All 
the compounds were subjected to elemental analysis (CHN) and the measured values agreed 
within ±0.4 % with the calculated ones. Thin layer chromatography was performed on silica 
gel G (Merck). The spots were developed in an iodine chamber and visualized with an ultra-
violet lamp. The solvent systems used were benzene:acetone (8:2, v/v) and toluene:ethyl ace-
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tate:formic acid (5:4:1, v/v). Ashless Whatman No. 1 filter paper was used for vacuum fil-
tration. The IR spectra were recorded in KBr pellets on a (BIO-RAD FTS 135) WIN-IR spec-
trophotometer. The FAB mass spectra of all the compounds were recorded on a JEOL SX102/  
/DA-600 mass spectrometer using argon/xenon (6 kV, 10 mA) as the FAB gas. The 1H-NMR 
spectra were recorded on a Bruker model DPX 300 FT-NMR spectrometer in CDCl3 using 
tetramethylsilane (Me4Si, TMS) as an internal standard. The chemical shifts are reported in 
the δ ppm scale. 
General procedure for the preparation of the new (E)-N’-(substituted benzylidene)-
isonicotinohydrazides (1a–h) 
To an equimolar methanolic solution of isonicotinic acid hydrazide (0.1 mol) and sub-
stituted benzaldehyde (0.1 mol), a few drops of glacial acetic acid were added. The mixture 
was then refluxed on water bath for 5–6 h. It was then allowed to cool, poured onto crushed 
ice and recrystallised from methanol. 
General procedure for the preparation of the new N-(2-(substituted phenyl)-4-oxothiazolidin- 
-3-yl)isonicotinamides (2a–h) 
A mixture of 1 (0.01 mol) and thioglycolic acid (0.01 mol) was heated on an oil-bath at 
120–125 °C for 12 h. The reaction mixture was cooled and treated with 10 % sodium bi-
carbonate solution. The product was isolated and recrystallised from methanol–dioxane (4:1). 
General procedure for the preparation of new 2-(2-(2-substituted phenyl)-3-(isonicotin-
amido)-4-oxothiazolidin-5-yl)acetic acids (3a–h) 
A mixture of 1 (0.01 mol) and thiomalic acid (0.01 mol) was heated on an oil-bath at 
120–125 °C for 12 h. The reaction mixture was cooled and treated with 10 % sodium bi-
carbonate solution. The product was isolated and recrystallised from methanol–dioxane (4:1). 
General procedure for the synthesis of N-(3-chloro-2-(2-substituted phenyl)-4-oxoazetidin-1- 
-yl)isonicotinamide (4a–h) 
A solution of 1 (0.01 mol) in dioxane (20 mL) was added to a well-stirred mixture of 
chloroacetyl chloride (0.012 mol) and triethylamine (Et3N) (0.012 mol) in dioxane (10 mL) at 
0–5 °C. The reaction mixture was then stirred for 8 h, kept for 2 days at room temperature and 
then treated with cold water. The solid thus obtained was filtered, washed with water and re-
crystallised from methanol. 
General procedure for the synthesis of 1-(2-(2-substituted phenyl)-5-(pyridin-4-yl)-1,3,4- 
-oxadiazol-3(2H)-yl)ethanone (5a–h) 
A mixture of 1 (0.003 mol) and acetic anhydride (10 mL) was heated under reflux for 4 
h. After the reaction mixture attained room temperature, the excess acetic anhydride was 
decomposed by water and the mixture was stirred for further 30 min. The separated product 
was filtered, washed with water, dried and recrystallised from appropriate solvent systems.  
Biological evaluation 
Animals. Adult Wistar strain rats of either sex weighing 150–200 g were used for the 
evaluation of the anti-inflammatory, ulcerogenic and lipid peroxidation activities, whereas 
Swiss albino mice weighing 25–30 g were used for assessing the analgesic activity. The ani-
mals were allowed food and water ad libitum except during the experiments. They were 
housed in a room at 25±2 °C, and 50±5 % relative humidity with a 12 h light/dark cycle. The 
animals were randomly allocated into groups at the beginning of all the experiments. All the 
experimental protocols were performed with permission from the Institutional Animal Ethics 
Committee (IAEC), form No. 520. The animals were obtained from the Central Animal House 
2011 Copyright (CC) SCS
_________________________________________________________________________________________________________________________ Available online at www.shd.org.rs/JSCS/1060 GILANI  et al. 
Facility, Hamdard University, New Delhi-110062, India. Registration number and date of re-
gistration of the Animal House Facility (173/CPCSEA, 28, JAN-2000). All the test com-
pounds and the reference drug were administered orally suspended in 0.5 % carboxymethyl 
cellulose (CMC) solutions. 
Anti-inflammatory activity 
The synthesized compounds were evaluated for their anti-inflammatory activity using the 
carrageenan-induced hind paw edema method.21 The animals were randomly allocated into 
groups of six animals each and were fasted for 24 h before the experiment with free access to 
water. The control group received only 0.5 % carboxymethyl cellulose solution. The standard 
drug naproxen was administered orally at a dose of 10 mg kg-1. The test compounds were 
administered orally at an equimolar oral dose relative to 10 mg kg-1 naproxen. Into the sub- 
-plantar region of the right hind paw of each rat, 0.1 ml of 1 % carrageenan solution in saline 
was injected subcutaneously, 1 h after the administration of the test compounds or the stan-
dard drug. The right hind paw volume was measured before and after 3 and 4 h of carrageenan 
treatment by means of a plethysmometer. The percent edema inhibition was calculated from 
the mean effect in the control and treated animals according to the following equation: 
  Percent edema inhibition = (Vc – Vt /Vc)×100 
where Vt represents the mean increase in paw volume in rats treated with test compounds and 
Vc represents the mean increase in paw volume in the control group of rats. 
Analgesic activity 
The analgesic activity was evaluated by the tail immersion method.22 Swiss albino mice 
allocated into different groups consisting of six animals of either sex in each, weighing 25–30 
g, were used for the experiment. The analgesic activity was evaluated after oral administration 
of the test compounds at an equimolar dose relative to 10 mg kg-1 naproxen. The test com-
pounds and the standard drug were administered orally as a suspension in carboxymethyl cel-
lulose solution in water (0.5 %, w/v). The analgesic activity was assessed before and 4 h after 
the administration of test compounds and standard drug. The lower 5 cm portion of the tail 
was gently immersed into thermostatically controlled water at 55±0.5 °C. The time in seconds 
for tail withdrawal from the water was taken as the reaction time with a cut-off time of im-
mersion set at 10 s for both the control as well as the treated group of animals. 
Acute ulcerogenicity 
Acute ulcerogenicity was determined according to the method of Cioli et al.23 The ani-
mals were allocated into different groups consisting of six animals in each group. The ulcero-
genic activity was evaluated after oral administration of the test compounds at an equimolar 
dose relative to 30 mg kg-1 naproxen. The control group received only 0.5 % carboxymethyl 
cellulose solution. Food but not water was removed 24 h before administration of the test 
compounds. After the drug treatment, the rats were fed with a normal diet for 17 h and then 
sacrificed. The stomach was removed and opened along the greater curvature, washed with 
distilled water and cleaned gently by dipping in normal saline. The mucosal damage was exa-
mined by means of a magnifying glass. For each stomach the mucosal damage was assessed 
according to the following scoring system: 0.5, redness, 1.0, spot ulcers, 1.5, hemorrhagic 
streaks, 2.0, ulcers < 3, 3.0, ulcers > 3 but ≤ 5. The mean score of each treated group minus 
the mean score of control group was regarded as the severity index of gastric mucosal damage. 
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Lipid peroxidation 
Lipid peroxidation in the gastric mucosa was determined according to the method of 
Ohkawa et al.24 After screening for ulcerogenic activity, the gastric mucosa was scraped with 
two glass slides, weighed (100 mg) and homogenized in 1.8 ml of 1.15 % ice-cold KCl solu-
tion. The homogenate was supplemented with 0.2 ml of 8.1 % sodium dodecyl sulphate (SDS), 
1.5 ml of acetate buffer (pH 3.5) and 1.5 ml of 0.8 % thiobarbituric acid (TBA). The mixture 
was heated at 95 °C for 60 min. After cooling, the reactants were supplemented with 5 ml of 
the mixture of n-butanol and pyridine (15:1 v/v), shaken vigorously for 1 min and centrifuged 
for 10 min at 4000 rpm. The supernatant organic layer was removed and the absorbance 
measured at 532 nm using a UV/Vis spectrophotometer. The results were expressed as nmol 
MDA 100 mg-1 tissue, using an extinction coefficient 1.56×105 cm-1 M-1. 
Statistical analysis of data 
The data are expressed as mean±standard error of mean (SEM). In the anti-inflammatory, 
ulcerogenic and lipid peroxidation studies, statistical differences between the treatments and 
the standard were tested by one-way ANOVA followed by the Dunnett multiple comparison 
test. A value of p < 0.01 was considered significant. In analgesic activity study, the statistical 
differences in treatments and standard were tested by the paired Student’s t-test. 
RESULTS AND DISCUSSION 
Chemistry 
The key intermediates used in the synthesis of thiazolidin-4-ones 2a–h and 
3a–h, azetidin-2-one 4a–h and 1,3,4-oxadiazole derivatives 5a–h, (E)-N’-(2-sub-
stituted benzylidene)isonicotinohydrazides 1a–h were prepared starting from iso-
nicotinic acid hydrazide. The reaction of isonicotinic acid hydrazide with sub-
stituted benzaldehyde in refluxing methanol with few drops of glacial acetic acid 
gave the (E)-N’-(2-substituted benzylidene)isonicotinohydrazides 1a–h.  In the 
present study, the reaction of the substituted benzylidene isonicotinohydrazides 
1a–h with thioglycolic acid, thiomalic acid, chloroacetyl chloride and acetic an-
hydride in presence of various reagents gave the new thiazolidin-4-ones 2a–h and 
3a–h, azetidin-2-one 4a–h and 1,3,4-oxadiazole derivatives 5a–h, respectively.  
The synthesis routes to the compounds are outlined in Scheme 1. The ana-
lytical and spectral data of the newly prepared compounds are given in the sup-
plementary material to this paper. 
The IR spectra of compounds 1a–h showed absorption peaks at 3300, 1680 
and 1600 cm–1 due to N–H, C=O and –N=CH stretching vibrations. The appea-
rance of the stretching of the C=O of thiazolidinone, β-lactam ring and the acetyl 
of the oxadiazole ring at 1700, 1745 and 1660 cm–1, respectively, in the spectra 
of the derivatives, together with the C=O stretching at 1680 cm–1 confirmed the 
formation of the compounds 2a–h, 3a–h, 4a–h and 5a–h. 
The 1H-NMR spectra of compounds 1a–h revealed a multiplet at δ 7.72 and 
8.63 ppm for pyridine and δ 7.12–7.15 ppm for the aromatic ring and singlets at δ 
6.1 and 7.9 ppm for –NH and –N=CH, respectively. The disappearance of the 
singlet peak of –N=CH and presence of a singlet peak at δ 3.5, 10.0, 7.7 and 7.19 
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ppm of –CH2 of thiazolidinone, COOH, –N–CH and –CH oxadiazole, respecti-
vely, proved that these compounds participated in the cyclisation reaction and 
formed the desired compounds. 
 
Scheme 1.The synthesis routes to the title compounds. 
Anti-inflammatory activity 
The anti-inflammatory activities of the synthesized compounds 2a–h, 3a–h, 
4a–h and 5a–h were evaluated by the carrageenan-induced paw edema method 
of Winter et al.15 The compounds were tested at a 10 mg kg–1 oral dose and were 
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compared with the standard drug naproxen at the same oral dose. The tested 
compounds showed anti-inflammatory activity ranging from 31.81–84.54 % (Ta-
ble I), whereas the standard drug naproxen showed 81.86 % inhibition after 4 h. 
TABLE I. Biological data of isonicotinic aid hydrazide derivatives (anti-inflammatory and 
analgesic activities of the test compounds with reference to the control. Ulcerogenic and lipid 
peroxidation were compared with reference to the standard drug, i.e., naproxen. Data were 
only analyzed by the Student’s t-test for n = 6) 
Compd. R 
Anti-inflam- 
matoryactivity 
(% inhibition±SEM)
Analgesic 
activity (% in-
hibition±SEM)
Ulcerogenic ac-
tivity (severity 
index±SEM) 
(nmol MDA 
content± 
SEM)/100 mg 
tissue 
Control –  –  –  0.000±0.00  3.25±0.005 
Naproxen –  81.86±3.71
c 71.42±1.31
a 2.250±0.11 9.04±0.24 
2a  o-C6H4Cl 78.00±2.53
c 70.32±1.31
a 0.583±0.18
a 5.715±0.14
a 
2b  p-C6H4Cl 64.64±3.79
c 59.09±3.60
c 2.750±0.19
c 8.808±0.06
c 
2c  o-C6H4OH 57.57±3.45
c 65.15±1.51
c 1.000±0.31
c 7.904±0.19
c 
2d  m-C6H4OH  34.08±3.47c 44.05±3.76c  1.667±0.24
c 6.715±0.16
a 
2e  p-C6H4OCH3  39.54±2.27c 31.81±3.71c  2.140±0.11
c 8.155±0.14
c 
2f  p-C6H4F 82.81±2.17
a 71.57±1.85
a 0.666±0.16
a 5.608±0.02
a 
2g  o-C6H4NO2  84.24±0.95
a 72.42±1.31
a 0.510±0.08
a 5.876±0.13
a 
2h  p-C6H4N(CH3)2  65.15±1.51
c 59.23±3.71
c 2.427±0.14
c 8.128±0.06
c 
3a  o-C6H4Cl  77.27±1.92
c 70.45±3.26
a 0.833±0.24
c 6.110±0.04
a 
3b  p-C6H4Cl  63.63±1.96
c 54.28±3.76c  2.466±0.20
c 8.742±0.17
c 
3c  o-C6H4OH  68.93±3.60
c 62.85±1.65
c 0.917±0.12
c 7.788±0.10
c 
3d  m-C6H4OH  31.81±3.45c 47.27±2.73c  2.835±0.18
c 8.110±0.13
c 
3e  p-C6H4OCH3  56.81±1.94
c 66.46±2.38
c 0.814±0.24
c 7.337±0.16
c 
3f  p-C6H4F  75.00±2.53
c 70.04±1.64
a 0.541±0.10
a 6.854±0.14
a 
3g  o-C6H4NO2  82.27±1.84
a 72.72±1.66
a 0.516±0.11
a 5.788±0.10
a 
3h  p-C6H4N(CH3)2  59.09±3.60
c 49.54±2.27c  2.413±0.10
c 8.371±0.12
c 
4a  o-C6H4Cl 70.45±3.26
c 64.80±1.28
c 2.683±0.10
c 7.874±0.15
c 
4b  p-C6H4Cl 68.93±3.60
c 59.61±1.00
c 1.751±0.16
c 5.192±0.22
a 
4c  o-C6H4OH 84.54±1.94
a 73.06±2.61
a 0.517±0.25
a 6.651±0.17
a 
4d  m-C6H4OH  44.05±3.76c 57.14±2.20
c 1.836±0.11
c 7.327±0.19
c 
4e  p-C6H4OCH3  54.28±3.45c 44.19±2.76c  2.432±0.24
c 8.418±0.11
c 
4f  p-C6H4F 77.14±2.20
c 71.12±1.24
a 0.750±0.18
c 5.62±0.29
a 
4g  o-C6H4NO2  76.50±1.82
c 69.54±3.19
c 0.817±0.12
c 8.364±0.24
c 
4h  p-C6H4N(CH3)2  72.72±1.66
c 52.48±3.76c  1.342±0.23
c 7.821±0.14
c 
5a  o-C6H4Cl 82.86±1.84
a 70.45±3.26
a 0.750±0.14
c 7.51±0.68
c 
5b  p-C6H4Cl 69.23±3.71
c 62.69±1.65
c 1.967±0.17
c 7.441±0.12
c 
5c  o-C6H4OH 63.46±2.38
c 55.32±1.96
c 1.834±0.22
c 7.652±0.17
c 
5d  m-C6H4OH  51.28±3.61
c 42.45±3.16c  2.667±0.14
c 8.345±0.19
c 
5e  p-C6H4OCH3  31.81±3.41
c 57.80±2.84
b 1.684±0.26
b 6.791±0.13
a 
5f  p-C6H4F 76.92±1.58
b 71.72±1.66
a 0.667±0.18
a 6.338±0.20
a 
5g  o-C6H4NO2  83.80±1.85
a 72.52±1.00
a 0.412±0.11
a 5.742±0.17
a 
5h  p-C6H4N(CH3)2  68.26±2.31
b 61.82±1.65
b 1.327±0.20
b 7.155±0.22
b 
ap < 0.0001; 
bp < 0.001; 
cp < 0.01 
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The anti-inflammatory activities of the thiazolidin-4-one derivatives (2a–h 
and 3a–h) were in the range 34.08–84.24 %. When the CH2 of thiazolidin-4-one 
moiety (2a–h) at the position 5 was substituted by CH2COOH (3a–h), no sub-
stantial change was observed in the activity. It was observed that thaiazolidin-4- 
-one derivatives having o-Cl, p-F and o-NO2 phenyl group showed better or equi-
valent activity (78.00, 82.81, 84.24 (in series 2), 77.27, 75.00 and 82.27 % (in 
series 3), respectively) to that of the standard drug. The other thiazolidin-4-one 
derivatives showed moderate activity.  
The anti-inflammatory activities of the azetidin-2-one derivatives were be-
tween 44.05 and 84.54 %. The highest activity (84.54 %) was found with the aze-
tidin-2-one derivative 4c having an o-hydroxyphenyl group at the position 4. It 
was observed that the azetidin-2-one derivative having a p-dimethylaminophenyl 
group (4h)  also showed good activity, viz. 72.72 % as did those having an 
o-chloro, p-fluoro and o-nitrophenyl group (70.45, 77.14 and 76.50 %, respecti-
vely). The other derivatives showed moderate activity. 
The 1,3,4-oxadiazole derivatives of isonicotinic acid hydrazide showed anti- 
-inflammatory activities ranging from 31.81 to 83.80 %.The highest activity 
(83.80 %) of the oxadiazole derivative was found for compound 5g having a 
o-nitrophenyl group at the position 2. When this group was replaced by the 
o-chloro phenyl group, the activity was found to be decreased but equivalent to 
that of the standard drug (82.86 %). Furthermore, the oxadiazole derivative having 
a p-fluorophenyl group (5f) at the position 2 also showed good activity (76.92 
%). The remaining oxadiazole derivatives showed moderate activity. 
Analgesic activity 
The thiazolidin-4-one derivatives 2f, 2g and 3g showed analgesic activities 
ranging from 71.57 to 72.72 %, i.e., better than that of the standard drug napro-
xen (71.42 %). The presence of a o-nitrophenyl group, at the position 2 of the 
thiazolidinone ring (2g and 3g) gave the maximum activity (72.42  and 72.72 %, 
respectively). When this group was replaced by o-chlorophenyl (2a and 3a) and 
p-fluorophenyl (2f and 3f), the activity was found to be slightly decreased 
(70.32–71.57 %). When these groups were replaced by p-OCH3 and m-OH phe-
nyl group (2e and 3d), the activity decreased drastically (31.81 and 47.27 %, res-
pectively). The results show that an electron-withdrawing group increased the 
analgesic activity of the compounds. 
When the thiazolidin-4-one nucleus was replaced by the azetidin-2-one nuc-
leus, the analgesic activity of most of the compounds decreased, except for com-
pound 4c having an o-hydroxylphenyl group at the position 4, which exhibited 
the highest activity (73.06 %). 1,3,4-Oxadiazole derivatives (5a–h) were also 
screened and showed 42.45–72.52 % analgesic activity. The compounds having a 
p-fluorophenyl (5f) and a o-nitrophenyl group (5g) at the position 2 of the oxa-
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diazole nucleus showed a slight difference in their activity (71.72 and 72.52 %). 
There was a decrease in the activity when these groups were replaced by an m- 
-hydroxyphenyl group (5d). 
Acute ulcerogenesis 
The tested compounds showed significant reductions in ulcerogenic activity, 
ranging from 0.417±0.08 to 2.835±0.18, whereas the standard drug naproxen ex-
hibited a high severity index (2.250±0.11). The ulcerogenic activity of the thiazo-
lidin-4-one derivatives 2a–h and 3a–h ranged from 0.510±0.08 to 2.835±0.18. 
The compounds with a o-nitrophenyl group (2g and 3g) showed minimum ulce-
rogenic activity (0.510±0.08 and 0.516±0.11, respectively). Moreover, their anti- 
-inflammatory activity was found to be high viz. 84.24 and 82.27 %, respectively. 
The other three thiazolidinone derivatives 2a, 2f and 3f also showed reductions in 
ulcerogenic activity (0.583±0.08, 0.666±0.16 and 0.541±0.10, respectively) in 
comparison to the standard drug.  
The azetidin-2-one derivatives 4c, 4f and 4g also showed reductions in ulce-
rogenic activity (0.517±0.11, 0.750±0.14 and 0.817±0.13). The 1,3,4-oxadiazole 
derivatives showed minimal ulcerogenic activity, when compared to the thiazoli-
din-4-one and azetidin-2-one derivatives. Compound 5g having a o-nitrophenyl 
group showed the minimum severity index (0.412±0.11). 
Lipid peroxidation 
It was reported in the literature that compounds showing less ulcerogenic 
activity also showed reduced malondialdehyde (MDA) content, a by-product of 
lipid peroxidation.25 Therefore, an attempt was made to correlate the decrease in 
ulcerogenic activity of the compounds with that of lipid peroxidation. All the 
compounds screened for ulcerogenic activity were also analyzed for lipid peroxi-
dation. 
The lipid peroxidation was measured as nmol of MDA per 100 mg of tissue. 
The naproxen (standard drug) showed the maximum lipid peroxidation (9.04±  
±0.24), whereas the control group showed 3.25±0.05. It was found that all the 
cyclised derivatives showing lower ulcerogenic activity also exhibited reduced 
lipid peroxidation (Table I). Thus, these studies showed that the synthesized 
compounds inhibited the induction of gastric mucosal lesions and the results fur-
ther suggested that their protective effect might be related to the inhibition of 
lipid peroxidation in the gastric mucosa. 
CONCLUSIONS 
Various thiazolidin-4-one, azetidin-2-one and 1,3,4-oxadiazole derivatives of 
isonicotinic acid hydrazide were prepared with the objective of developing better 
anti-inflammatory molecules with minimum ulcerogenic activity. It was interest-
ing to note that six of the cyclised compounds, 2f, 2g, 3g, 4c, 5a and 5g, were 
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found to have anti-inflammatory activity greater than that of the standard drug 
(naproxen, 81.86 %) at 10 mg kg–1 p.o. Furthermore, five compounds, 2a, 3a, 4f, 
4g and 5f, exhibited anti-inflammatory activity equivalent to the standard drug in 
the carrageenan-induced paw edema test in rats. When these compounds were 
subjected to the analgesic activity test, they showed increased activity over the 
reference drug. 
The presence of p-fluorophenyl and o-nitrophenyl groups at the 2nd position 
of the thiazolidinone nucleus increased the anti-inflammatory activity whereas 
the presence of m-hydroxryphenyl and p-methoxyphenyl groups decreased the 
anti-inflammatory activity. It was further noted that the presence of o-hydroxy, o- 
-chloro and o-nitrophenyl groups at the and positions 4 and 2 of azetidinone and 
oxadiazole nucleus, respectively, increased the anti-inflammatory activity com-
pared to the standard drug, whereas presence of the p-fluorophenyl group showed 
anti-inflammatory activity slightly less than that of the standard drug. 
These compounds tested for ulcerogenic activity showed a significant de-
crease in activity compared to that of the standard drug. It was noted that the oxa-
diazole derivatives showed maximum reduction in ulcerogenic activity followed 
by the thiazolidinone and azetidinone derivatives. It was further concluded that 
the presence of p-fluorophenyl and o-nitrophenyl groups at the positions 2, 4 and 
2 of thiazolidione, azetidinone and oxadiazole nucleus, respectively, showed maxi-
mum anti-inflammatory and analgesic activity, minimum ulcerogenic activity 
together with minimum lipid peroxidation. 
SUPPLEMENTARY MATERIAL 
Analytical and spectral data of the synthesized compounds are available electronically at 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
ТИАЗОЛИДИН-4-ОНСКИ, АЗЕТИДИН-2-ОНСКИ И 1,3,4-ОКСАДИАЗОЛСКИ ДЕРИВАТИ 
ХИДРАЗИДА ИЗОНИКОТИНСКЕ КИСЕЛИНЕ: СИНТЕЗА И 
ЊИХОВА БИОЛОШКА АКТИВНОСТ 
SADAF J. GILANI
1,2, SUROOR A. KHAN
1, OZAIR ALAM
1, VIJENDER SINGH
2 и ALKA ARORA
2 
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi-110062 и 
2Department of Pharmaceutical Chemistry, KIET School of Pharmacy, Ghaziabad, U.P. 201206, India 
Синтетисана  је  серија  нових  тиазолидин-4-онских ( 2a–h  и 3a–h),  азетидин-2-oнских 
(4a–h) и 1,3,4-оксадиазолских (5a–h) деривата хидразида изоникотинске киселине (INH) са 
циљем да се испита њихова анти-инфламаторна, аналгетичка и улцерогена активност и ак-
тивност  према  пероксидацији  липида.  Структура  синтетисаних  једињења  одређена  је  на 
основу IC, NMR и масених спектара. Анти-инфламаторна активност једињења одређена је 
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тестом карагененом идукованог отока на шапи пацова. Од 32 испитана једињења, 11 пока-
зује  врло  добру  анти-инфламаторну  активност  и  изражену  аналгетичку  активност,  уз 
незнатну улцерогену активност. Једињења која показују најмању улцерогену активност до-
воде до снижавања количине малондиалдехида (MDA), који је споредни производ липидне 
пероксидације. Резултати показују да једињења инхибирају индукцију оштећења слузокоже 
желуца  и  може  се  претпоставити  да  је  њихова  заштитна улога  повезана са  инхибицијом 
липидне пероксидације у слузокожи желуца. 
(Примљено 4. новембра 2009, ревидирано 2. априла 2011) 
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